National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Eltrombopag (Revolade®) is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

Rapid Review

Commenced Completed Outcome
10/01/2014 13/02/2014 Full Pharmacoeconomic Evaluation not Recommended.